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Abstract
Ventilator-associated pneumonia (VAP) as a result of multidrug-resistant Gram-negative bacteria has contributed to the revival of the
use of intravenous (i.v.) colistin. However, the additional administration of inhaled colistin for VAP is controversial. We performed a
retrospective cohort study of patients with microbiologically documented VAP who received i.v. colistin with or without inhaled colis-
tin. Seventy-eight patients with VAP received i.v. plus inhaled colistin, whereas 43 patients received i.v. colistin alone. The mean ± SD
daily dosage of i.v. colistin was 7.0 ± 2.4 and 6.4 ± 2.3 million international units (IU), respectively (p 0.13); the average daily dosage of
inhaled colistin was 2.1 ± 0.9 million IU. The outcome of infection was cure for 62/78 (79.5%) patients who received i.v. plus inhaled
colistin vs. 26/43 (60.5%) patients who received i.v. colistin alone (p 0.025); all-cause in-hospital mortality was 31/78 (39.7%) vs. 19/43
(44.2%), respectively (p 0.63); all-cause intensive care unit (ICU) mortality was 28/78 (35.9%) vs. 17/43 (39.5%), respectively (p 0.92).
The use of inhaled colistin was independently associated with the cure of VAP in a multivariable analysis (OR 2.53, 95% CI 1.11–5.76).
Independent predictors of mortality were a higher APACHE II score (OR 1.12, 95% CI 1.04–1.20), presence of malignancy (OR 4.11,
95% CI 1.18–14.23) and lower daily dosage of i.v. colistin (OR 0.81, 95% CI 0.68–0.96). The outcome of VAP was better in patients
who received inhaled colistin with i.v. colistin than those who received i.v. colistin alone. There was no difference in all-cause in-hospital
and ICU mortality between the two groups. Randomized controlled trials are needed to evaluate further the role of inhaled colistin in
VAP.
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Introduction
Ventilator-associated pneumonia (VAP) is the most common
nosocomial infection in the intensive care unit (ICU) setting
[1]. Among the pathogens implicated in the pathogenesis of
VAP, Pseudomonas aeruginosa and Acinetobacter baumannii are
the predominant species and, together with methicillin-resis-
tant Staphylococcus aureus, account for the highest attributable
mortality [2]. Timely administration of appropriate antibiotic
therapy contributes to better clinical outcomes of VAP [3].
Increasingly recently, strains of P. aeruginosa and A. bau-
mannii, and other Gram-negative bacteria such as Klebsiella
pneumoniae, exhibit co-resistance to almost all antibiotic clas-
ses, including carbapenems [4,5]. Considering that there are
few new antimicrobials for multidrug resistant (MDR) Gram-
negative bacteria in development [6], attention has been
focused on the potential use of the old antibiotic colistin to
treat infections caused by resistant strains [7,8].
Colistin acts in a way that does not promote cross-resis-
tance and is unlikely to be associated with the rapid selection
of resistant strains [9]. Administration of intravenous (i.v.)
colistin in patients with ICU-acquired infections caused by
MDR Gram-negative bacteria has shown a favourable clinical
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outcome [10–12]. Inhaled colistin has been used successfully
for over 20 years to prevent and cure pulmonary infections
as a result of P. aeruginosa in patients with cystic ﬁbrosis
[13]. There are very few data available addressing whether
inhaled colistin is effective for the treatment of nosocomial
pneumonia and particularly VAP [14,15].
Considering the high mortality of VAP, it is important to
know whether inhaled colistin confers an additive treatment
beneﬁt to standard treatment. To address this issue, we retro-
spectively analyzed the outcome of VAP caused by MDR
Gram-negative pathogens in patients treated with the combi-
nation of i.v. plus inhaled colistin compared to i.v. colistin
alone, regardless of concomitant treatment with other classes
of antibiotics.
Materials and Methods
Data for this retrospective analysis were collected for
patients hospitalized between May 2005 and August 2007 at
‘Henry Dunant’ Hospital, a 450-bed tertiary-care centre in
Athens, Greece. Ethical approval for the study had been
granted from the hospital’s review board.
Study design
All patients who had received colistin (Colomycin, Forest
Laboratories, Kent, UK, or Colistin, Norma, Athens,
Greece) were identiﬁed from the database of the hospital’s
central pharmacy and all available relevant medical records
were retrieved for analysis. One milligram of the colistin for-
mulations used corresponds to 12 500 international units
(IU) (Forest Laboratories) or 13 333 IU (Norma).
Patients were included in the study if they had a diagnosis
of microbiologically documented VAP and received colistin
administered either i.v. or i.v. in combination with inhaled
colistin. Received i.v. colistin must have been given for at
least 3 days and inhaled colistin for at least 3 days or more
than 50% of the duration of the treatment with i.v. colistin.
Colistin therapy (either i.v. or inhaled) must have been initi-
ated within a period of 5 days before or after the day of the
culture specimen that yielded the pathogen responsible for
VAP (index culture). Days of treatment with other co-admin-
istered antibiotics were calculated from the day of the index
culture until the end of colistin treatment (i.v. or inhaled,
whichever was longer). In mechanically-ventilated patients,
inhaled colistin was delivered by means of the Siemens Servo
Ventilator 300 (Siemens-Elma AB, Solna, Sweden). In sponta-
neously breathing patients, 1000 000 IU of colistin were
added to 4 mL of normal saline and the solution was inhaled
with 8 L/min oxygen ﬂow and inhaled via a face mask.
Microbiological assays
All patients must have had a positive culture of a Gram-nega-
tive pathogen susceptible to colistin and no more than two
other antibiotic classes from tracheobronchial secretions or
bronchoalveolar lavage ﬂuid. Routine laboratory in vitro sus-
ceptibility testing to commonly used antibiotics was per-
formed with the automated broth microdilution method
(Vitek 2, (bioMe´rieux, Hazelwood, MO, USA). Susceptibility
to tigecycline was not evaluated because this agent was not
available for clinical use during most of the study period. The
susceptibility of P. aeruginosa, A. baumannii, and K. pneumoniae
isolates to colistin was determined by the the colistin Etest
strip method (AB Biodisk, Solna, Sweden) on Mueller–Hinton
agar inoculated with bacteria suspension equivalent to 0.5
McFarland standard, as recommended by the manufacturer
[16]. Isolates were designated as being susceptible to colistin
if the MIC was less than or equal to 2 mg/L; otherwise, they
were considered as resistant.
Collection and extraction of data
Baseline patient demographic data were recorded and tabul-
lated. Data were collected on transfusion of blood compo-
nents and other special treatments up until the isolation of
the Gram-negative pathogen responsible for VAP. Data on
renal replacement therapy and surgical interventions includ-
ing the placement of a foreign body were collected until the
day that colistin treatment was introduced.
Data on hospitalization and any other antimicrobial treat-
ment for the 3 months before the studied admission were
collected, as well as information on co-morbididities such as
diabetes mellitus, cancer, haematological, liver, respiratory,
cardiovascular; urinary, nervous diseases, HIV infection and
acute or chronic renal failure.
For all patients included in the study, the time of
mechanical ventilation, tracheal intubation, tracheostomy
tube, placement of a bladder or central venous catheter or
nasogastric tube, and administration of parenteral nutrition
was calculated. The Acute Physiology and Chronic Health
Evaluation (APACHE) II score on admission to the ICU
was calculated. The performance of invasive procedures
such as bronchoscopy, nephrostomy, gastrostomy, colos-
tomy, cystoscopy and placement of a pigtail catheter was
noted.
Deﬁnition of infection and outcomes
VAP was deﬁned according to the criteria of the American
Thoracic Society Consensus Conference on VAP; speciﬁcally,
by the presence of: fever greater than 38C with no other
recognized cause; leucopenia (<4 000 white blood cells/mm3)
or leukocytosis (‡12 000 white blood cells /mm3); purulent
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tracheal secretions; and new and persistent inﬁltrate on
chest X-ray, in patients being on mechanical ventilation sup-
port for at least 48 h. All episodes of VAP should have been
documented by quantitative cultures and microscopic exami-
nation of lower respiratory tract secretions [17].
The evaluated outcomes were the outcome of the infec-
tion, all-cause in-hospital mortality, and all-cause ICU mortal-
ity. The outcome of the infection was classiﬁed as resolution
(cure) or no resolution (stable condition or deterioration).
The resolution of the infection was deﬁned by the normaliza-
tion of body temperature and tracheal secretions, together
with a return to baseline of the white blood cell count and
the C-reactive protein level, and the improvement in chest
X-ray appearances, by the end of colistin treatment.
Statistical analysis
Variables were evaluated for normality of distribution by
the use of the Kolmogorov–Smirnov test. The distribution
of normally distributed variables between treatment groups
was compared using Student’s t-test. For non-normally dis-
tributed variables, the chi-square or Mann–Whitney signed
rank test was used for dichotomous or continuous vari-
ables, respectively. Variables signiﬁcantly associated with the
studied outcomes in the bivariable analyses were entered in
a multivariable backward, stepwise, logistic regression
model. For all tests, a two-tailed p £0.05 was considered as
statistically signiﬁcant. The analyses were performed using
the statistical software SPSS, version 15.0 (SPPS, Chicago,
IL, USA).
Results
Identiﬁed cases
We identiﬁed 205 patients who received i.v. colistin for
more than 3 days for a microbiologically documented infec-
tion during the period May 2005 to August 2007 inclusive.
Of these 205 patients, 55 were excluded from further anal-
ysis because they did not have a respiratory tract infection.
We also excluded 29 additional patients for other reasons,
including 15 with a colistin resistant pathogen, eight because
their medical records were not available, and six who
received inhaled colistin without concurrent i.v. administra-
tion. Among the remaining 121 patients, 78 received i.v.
plus inhaled colistin for the treatment of VAP, whereas 43
patients received i.v. colistin alone. Data for 42 of the 78
patients in the former group had previously been included
in a prospective cohort study that investigated the effective-
ness and safety of inhaled colistin as adjunctive treatment
of patients with VAP [18]. However, for the purposes of
this comparative analysis, we re-reviewed the relevant med-
ical records and collected additional data for this patient
subset.
The mean ± SD daily dose of inhaled colistin was 2.1 ± 0.9
million IU. The great majority (91.0%) of the group of patients
who received i.v. plus inhaled colistin started inhaled colistin
within 4 days of the i.v. administration. Eighteen of the patients
who received i.v. plus inhaled colistin were treated concur-
rently with other classes of antibiotics to which the causative
pathogens were susceptible. Of these, nine patients were trea-
ted, with a carbapenem, ﬁve with an aminoglycoside, two with
an aminoglycoside plus a carbapenem, one with a ﬂuoroquino-
lone plus a carbapenem, and one with an antipseudomonal
b-lactam/b-lactamase inhibitor. In the group of patients who
received inhaled colistin only, ﬁve patients received other anti-
biotics to which the causative pathogens were susceptible,
including three patients who were additionally treated with
an aminoglycoside, one with a carbapenem, and one with an
aminoglycoside plus a carbapenem.
Outcomes
Table 1 shows the demographic and clinical features of the
studied patients and their outcomes. The bivariable analyses
showed that blood transfusion, the duration of administra-
tion of i.v. colistin and infection with polymyxin-only suscep-
tible Gram-negative pathogens were differently distributed
between the two groups of patients. The outcome of infec-
tion was cure for 62/78 patients (79.5%) who received i.v.
plus inhaled colistin vs. 26/43 patients (60.5%) who received
i.v. colistin alone (p=0.025). The use of inhaled colistin was
the only independent variable signiﬁcantly associated with
the cure of VAP in the multivariable analysis (OR 2.53, 95%
CI 1.11–5.76). In the subset of patients who did not receive
any concomitant therapy with other microbiologically active
agents, the outcome of infection was cure for 46/60 patients
(76.7%) who received i.v. plus inhaled colistin vs. 22/38
patients (57.9%) who received i.v. colistin alone (p=0.049).
All-cause in-hospital mortality was 31/78 (39.7%) patients
who received i.v. plus inhaled colistin vs. 19/43 (44.2%)
patients who received i.v. colistin alone (p=0.63). All-cause
ICU mortality was 28/78 (35.9%) vs. 17/43 (39.5%), respec-
tively (p=0.69) .
In the subset of patients who did not receive concomitant
treatment with microbiologically active agents, all-cause in-
hospital mortality was 24/60 patients (40%) who received i.v.
plus inhaled colistin vs. 18/38 patients (47.4%) who received
i.v. colistin alone (p=0.47). All deaths occurred within
30 days of the initiation of colistin treatment, except for four
deaths (two in each group) that were noted beyond this per-
iod.
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The toxicity of colistin was not speciﬁcally assessed in the
present study. However, no serious adverse events of
inhaled colistin, such as bronchoconstriction, were recorded.
Table 2 shows the demographic and clinical features of
the patients who died compared to those who survived. The
bivariable analysis showed that older age, greater APACHE II
score, the presence of malignancy, haemodialysis treatment,
and a lower daily dosage of i.v. colistin were associated with
higher mortality. These variables, along with the type of
colistin treatment (i.v. plus inhaled vs. i.v. alone), were
entered into a multivariable analysis. A higher APACHE II
score (OR 1.12, 95% CI 1.04–1.20), the presence of
malignancy (OR 4.11, 95% CI 1.18–14.23) and a lower daily
dosage of i.v. colistin (OR per million IU 0.81, 95% CI
0.68–0.96) remained statistically signiﬁcant predictors of
mortality in this model.
Discussion
The present study demonstrated that the infection outcome
of VAP caused by MDR strains of Gram-negative pathogens
was better in patients who received inhaled colistin along
with i.v. colistin vs. i.v. colistin alone. The use of inhaled
colistin was an independent predictor of cure of VAP.
However, there was no difference in all-cause in-hospital
TABLE 1. Comparison of demo-
graphic and clinical characteristics,
including outcomes, of patients
with ventilator-associated pneumo-
nia treated with colistin intrave-
nous (i.v.) monotherapy and
colistin i.v. in combination with
inhaled colistin
Colistin i.v.
and inhaled
(n = 78)
Colistin i.v.
(n = 43) p value
Demographic
Age, years (mean ± SD) 59.2 ± 19.2 60.9 ± 15.7 0.89
Sex (male), n/N (%) 61/78 (78.2) 31/43 (72.1) 0.45
APACHE II score (mean ± SD) 17.4 ± 6 19.2 ± 7 0.15
Comorbidity, n/N (%)
Malignancy 10/78 (12.8) 7/43 (16.3) 0.6
Cardiovascular 33/78 (42.3) 25/43 (58.1) 0.10
Pulmonary 17/78 (21.8) 9/43 (20.9) 0.91
Diabetes mellitus 20/78 (25.6) 10/43 (23.3) 0.77
Urogenital 7/78 (9) 8/43 (18.6) 0.12
Chronic renal failure 7/78 (9) 3/43 (7) 0.70
Hepatic 3/78 (3.8) 0/43 (0) 0.55
Haematological 8/78 (10.3) 4/43 (9.3) 0.87
Neurological 19/78 (24.4) 5/43 (11.6) 0.09
AIDS 1/78 (1.3) 0/43 (0) 0.46
Previous hospitalization, n/N (%) 15/78 (19.2) 8/43 (18.6) 0.93
Previous antibiotic use, n/N (%) 25/78 (32.1) 11/43 (25.6) 0.46
Duration of hospitalization until the
ﬁrst day of colistin treatment, days
(mean ± SD)
16.6 ± 26.1 12 ± 8.3 0.72
Duration of ICU stay until the ﬁrst
day of colistin, days treatment
(mean ± SD)
11.7 ± 8.7 11.3 ± 8.4 0.73
Duration of mechanical ventilation
support until the ﬁrst day of colistin
treatment, days (mean ± SD)
8.9 ± 6.1 8.4 ± 6.5 0.54
Special treatments, n/N (%)
Blood transfusion 52/78 (66.7) 36/43 (83.7) 0.04
Haemodialysis 11/78 (14.1) 8/43 (18.6) 0.51
Growth factors 8/78 (10.3) 6/43 (14) 0.54
Urinary catheter, n/N (%) 78/78 (100) 43/43 (100) NA
Tracheostomy, n/N (%) 56/78 (71.8) 31/43 (72.1) 0.97
Bronchoscopy, n/N (%) 17/78 (21.8) 4/43 (9.3) 0.08
Antibiotic use after the initiation of colistin, days (mean ± SD)
Antipseudomonal penicillin 2.5 ± 5.3 1.8 ± 2.9 0.97
Aminoglycosides 2.2 ± 4.4 2.1 ± 4.7 0.96
Fluoroquinolones 1.9 ± 3.7 1.7 ± 2.7 0.68
Carbapenems 11.1 ± 9.8 8.9 ± 5.8 0.34
Rifampicin 0.6 ± 2 0.2 ± 1 0.28
Treatment with additional active antibiotics 18/78 (23.1) 5/43 (11.6) 0.124
Intravenous colistin, days (mean ± SD) 16.9 ± 9.8 13.7 ± 11.2 0.013
Dosage of i.v. colistin, IU (mean ± SD) (7.0 ± 2.4) · 106 (6.4 ± 2.3) · 106 0.13
Responsible pathogen, n/N (%)
Acinetobacter baumannii 57/78 (73.1) 35/43 (81.4) 0.30
Pseudomonas aeruginosa 17/78 (21.8) 5/43 (11.6) 0.16
Klebsiella pneumoniae 4/78 (5.1) 3/43 (7) 0.68
Antimicrobial susceptibility, n/N (%)
Polymyxin-only susceptible 37/78 (47.4) 31/43 (72.1) 0.009
Outcomes, n/N (%)
Infection outcome (cure) 62/78 (79.5) 26/43 (60.5) 0.025
Mortality 31/78 (39.7) 19/43 (44.2) 0.63
ICU mortality 28/78 (35.9) 17/43 (39.5) 0.69
ICU, intensive care unit; IU, international units.
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mortality and all-cause ICU mortality between the two
groups.
It is important to determine whether inhaled antibiotics
can improve the outcome of VAP [19]. It has been assumed
that the delivery of antibacterials directly to the site of infec-
tion is clinically beneﬁcial by increasing topical drug levels
[20,21]. Inhaled antibiotics such as tobramycin, amikacin and
colistin have mainly been used to treat patients with cystic
ﬁbrosis with generally favourable results [22,23].
In the present study, patients in the i.v. plus inhaled colis-
tin group received i.v. colistin for a longer period of time
than patients in the i.v. colistin alone group (Table 1).
Because more patients in the i.v. plus inhaled colistin group
showed clinical improvement, it is plausible that these
patients received the full course of treatment for VAP
caused by nonfermentative Gram-negative pathogens, which
is approximately 2–3 weeks [24].
Furthermore, patients in the i.v. colistin alone group were
more likely to be infected by polymyxin-only susceptible
pathogens compared to those in the i.v. plus inhaled colistin
group. This may reﬂect a more protracted clinical course
prior to the index episode of VAP. However, the proportion
of patients who received treatment with other microbiologi-
cally active agents did not differ signiﬁcantly between the
two colistin treatment groups.
The present study demonstrated no difference in all-cause
in-hospital and ICU mortality between patients who received
inhaled plus i.v. colistin and those who received i.v. colistin
alone. A relatively high mortality is expected for such
patients as a result of serious co-morbidity [25]; APACHE II
TABLE 2. Predictors of mortality
(univariate analysis)
Died
(n = 50)
Survived
(n = 71) p value
Demographic
Age, years (mean ± SD) 64.4 ± 15.7 56.6 ± 18.9 0.028
Sex (male), n/N (%) 39/50 (78) 53/71 (74.6) 0.67
APACHE II score (mean ± SD) 20.5 ± 6.2 16.3 ± 6.0 0.001
Comorbidity, n/N (%)
Malignancy 12/50 (24) 5/71 (7) 0.008
Cardiovascular 29/50 (58) 29/71 (40.8) 0.06
Pulmonary 12/50 (24) 14/71 (19.7) 0.57
Diabetes mellitus 16/50 (32) 14/71 (19.7) 0.12
Urogenital 7/50 (14) 8/71 (11.3) 0.65
Chronic renal failure 6/50 (12) 4/71 (5.6) 0.21
Hepatic 1/50 (2) 2/71 (2.8) 0.78
Haematological 7/50 (14) 5/71 (7) 0.21
Neurological 8/50 (16) 16/71 (22.5) 0.38
AIDS 0/50 (0) 1/71 (1.4) 0.40
Previous hospitalization, n/N (%) 11/50 (22) 12/71 (16.9) 0.48
Previous antibiotic use, n/N (%) 18/50 (36) 18/71 (25.4) 0.21
Duration of hospitalization until the
ﬁrst day of colistin treatment, years
(mean ± SD)
17.5 ± 29.0 13.2 ± 21.6 0.31
Duration of ICU stay until the ﬁrst day
of colistin treatment, years (mean ± SD)
11.9 ± 8.5 11.3 ± 8.7 0.66
Duration of mechanical ventilation support
until the ﬁrst day of colistin treatment,
years (mean ± SD)
9.3 ± 5.9 8.4 ± 6.5 0.32
Special treatments, n/N (%)
Blood transfusion 39/50 (78) 49/71 (69) 0.27
Haemodialysis 13/50 (26) 6/71 (8.5) 0.009
Growth factors 9/50 (18) 5/71 (7) 0.06
Urinary catheter, n/N (%) 50/50 (100) 71/71 (100) NA
Tracheostomy, n/N (%) 38/50 (76) 49/71 (69) 0.4
Bronchoscopy, n/N (%) 11/50 (22) 10/71 (14.1) 0.26
Antibiotic use after the initiation of colistin,
days (mean ± SD)
Antipseudomonal penicillin 2.0 ± 3.5 2.4 ± 5.2 0.80
Aminoglycosides 2.3 ± 4.2 2.0 ± 4.7 0.27
Fluoroquinolones 1.6 ± 2.7 2.0 ± 3.8 0.66
Carbapenems 10.4 ± 10.2 10.3 ± 7.3 0.58
Rifampicin 0.5 ± 1.8 0.4 ± 1.6 0.57
Intravenous colistin, days (mean ± SD) 14.5 ± 8.5 16.7 ± 11.5 0.50
Dosage of i.v. colistin, IU (mean ± SD) (5.9 ± 2.3) · 106 (7.4 ± 2.2) · 106 0.001
Responsible pathogen, n/N (%)
Acinetobacter baumannii 34/50 (68) 58/71 (81.7) 0.08
Pseudomonas aeruginosa 13/50 (26) 9/71 (12.7) 0.06
Klebsiella pneumoniae 3/50 (6) 4/71 (5.6) 0.93
Antimicrobial susceptibility, n/N (%)
Polymyxin-only susceptible 32/50 (64) 36/71 (50.7) 0.15
Outcomes, n/N (%)
Infection outcome (cure) 17/50 (34) 71/71 (100) 0.001
Colistin use (i.v. plus inhaled) 31/50 (62) 47/71 (66.2) 0.64
ICU, intensive care unit; IU, international units.
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score and malignancy were predictors of mortality in our
cohort.
Colistin is recommended in the latest guidelines of the
American Thoracic Society as a last therapeutic resort for
the treatment of VAP and is usually administered in patients
with the most severe clinical condition [3]. Some studies
have shown that the administration of inhaled colistin should
not be accompanied with a decrease in the dosage of i.v.
administered colistin, which may be performed to prevent
dose-related toxicity, particularly nephrotoxicity [26]. Simi-
larly, in our cohort of patients, a lower i.v. colistin daily dos-
age was independently related to higher mortality.
The present study has some limitations. Inhaled colistin was
usually administered via conventional nebulizers, which do not
control the particle size, and therefore the actual amount of
the drug delivered to the lungs could not be accurately esti-
mated [27,28]. In addition, the present study has the inherent
limitations of a retrospective analysis. However, this is the
only comparative evidence available so far that addresses the
issue of the usefulness of inhaled colistin for VAP.
In conclusion, the present study demonstrated a better
outcome in the treatment of VAP as a result of MDR Gram-
negative pathogens when inhaled colistin was used in combi-
nation with i.v. colistin compared to i.v. colistin alone. There
was no difference with respect to all-cause in-hospital and
ICU mortality between the two groups. Well-designed ran-
domized controlled trials are needed to verify the additional
beneﬁts of inhaled colistin in this setting.
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